You just read:

OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Feb 12, 2013, 08:00 EST